Health Partners Medicare

PRIOR AUTHORIZATION REQUEST FORM

Juxtapid - Medicare

Phone: 215-991-4300 **Fax back to: 866-371-3239**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: ☐ Medicare	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	**Specialty/facility name (if applicable):**

☐ REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.

Q1. Is Juxtapid being prescribed by or in consultation with an endocrinologist, cardiologist, or lipid specialist?

☐ Yes ☐ No

Q2. Is the patient 18 years of age or older?

☐ Yes ☐ No

Q3. Does the patient have a confirmed diagnosis of homozygous familial hypercholesterolemia and attached lipid profile?
Please submit genetic testing.

☐ Yes ☐ No

Q4. Is the patient a male or a nonreproductive female?

☐ Yes ☐ No

Q5. Does the patient have a negative pregnancy test and will pregnancy status be monitored throughout the course of treatment?

☐ Yes ☐ No

Q6. Does the patient have moderate or severe hepatic impairment (based on Child-Pugh category B or C) or active liver disease including unexplained persistent elevations of serum transaminases?

☐ Yes ☐ No

Q7. Will Juxtapid be used in combination with moderate or strong cytochrome P3A4 (CYP3A4) inhibitors?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Health Partners Medicare

PRIOR AUTHORIZATION REQUEST FORM

Juxtapid - Medicare

Phone: 215-991-4300 **Fax back to: 866-371-3239**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**

☐ Yes ☐ No

Q8. Is this a request for a continuation of therapy?

☐ Yes ☐ No

Q9. Has the patient had previous treatment with inadequate response, intolerance, or contraindication to standard lipid-lowering regimen containing high potency statins (atorvatstatin 40 mg or 80 mg OR rosuvastatin 20 mg or 40 mg)?
Please attach documentation with explanation of intolerance or contraindication.

☐ Yes ☐ No

Q10. Has the patient had previous treatment with inadequate response, intolerance, or contraindication to utilizing a PCSK9 inhibitor (Repatha) to manage the condition?
Please attach documentation with explanation of intolerance or contraindication.

☐ Yes ☐ No

Q11. Has a post-treatment liver function tests and lipid profile been submitted for review?
Please attach documentation

☐ Yes ☐ No

Q12. Will Juxtapid be used in combination with other lipid-lowering treatments such as statins, fenofibrates, ezetimibe, or niacin?

☐ Yes ☐ No

Q13. Additional Information:

Q14. Requested Duration:

☐ 6 months

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document